NBC TODAY on Foundayo (Oral GLP-1 Pill): Fact Check
NBC's TODAY show aired a segment on April 2, 2026 covering the FDA approval of Eli Lilly's new oral GLP-1 pill. The segment, reported by Anne Thompson, covers the drug's convenience advantages, weight loss data, pricing, and how it compares to the Wegovy pill. Below, we fact-check every major claim against published clinical trial data and FDA records.
The Drug Name Error
The segment repeatedly calls the new pill "Zepbound." This is the most significant factual error in the segment. The drug is actually called Foundayo (orforglipron) — a completely different medication from Zepbound (tirzepatide).
| TODAY's Claim | Published Facts | Verdict |
|---|---|---|
| Eli Lilly's new GLP-1 pill called Zepbound | The FDA-approved oral pill is Foundayo (orforglipron), a non-peptide small molecule GLP-1 agonist. Zepbound is the brand name for injectable tirzepatide, a GLP-1/GIP dual agonist — an entirely different drug with a different mechanism. | Wrong drug name |
This matters because Zepbound and Foundayo are fundamentally different medications. Zepbound (tirzepatide) is a peptide that targets two receptors (GLP-1 and GIP) and produces about 22.5% weight loss as a weekly injection. Foundayo (orforglipron) is a small molecule that targets only GLP-1 and produces about 12.4% weight loss as a daily pill. Confusing the two could mislead patients about what they are taking and what results to expect.
For more on how these drugs differ, see our Foundayo (orforglipron) explainer and orforglipron vs Zepbound comparison.
No Empty Stomach Required
The segment highlights that the new pill can be taken at any time of day without regard to food — unlike the Wegovy pill, which requires fasting.
| TODAY's Claim | Published Facts | Verdict |
|---|---|---|
| You can take it anytime a day without regard to food | Foundayo's FDA label confirms it can be taken at any time of day, with or without food, with no water restrictions. The Wegovy pill (oral semaglutide) requires an empty stomach, a sip of water only, and a 30-minute fast before eating. | Accurate |
This is one of Foundayo's genuine advantages. Because orforglipron is a non-peptide small molecule (not a peptide like semaglutide), it survives stomach acid and doesn't need the absorption-enhancing formulation that forces fasting requirements on peptide-based oral drugs.
For more on oral vs injectable GLP-1 drugs, see our oral vs injection comparison.
Weight Loss Data
| TODAY's Claim | Published Trial Data | Verdict |
|---|---|---|
| Highest dose: 12% body weight loss, about 27 pounds | ATTAIN-1 trial (72 weeks): 17.2 mg dose produced 12.4% mean weight loss (27.3 lbs). 59.6% of patients lost 10%+ and 39.6% lost 15%+. | Accurate |
| Not as effective as the injections | Correct. Foundayo 12.4% vs Wegovy injection 16% vs Zepbound injection 22.5%. However, the Wegovy pill (oral semaglutide 25 mg) achieves 15-17%, which is closer. | Accurate |
The weight loss numbers cited in the segment closely match the published ATTAIN-1 trial data. The 12% figure is slightly rounded down from the actual 12.4%, and 27 pounds is consistent with the 27.3 lbs reported in the trial. The segment also correctly notes that pills are less effective than injections.
Pricing Claims
| TODAY's Claim | Published Pricing | Verdict |
|---|---|---|
| $149/month for starter dose | Foundayo 0.8 mg starter dose: $149/month (self-pay via LillyDirect or GoodRx) | Accurate |
| Up to $349 a month | $349/month applies to the 14.5 mg and 17.2 mg doses only if refills are delayed beyond 45 days. With timely refills, maintenance doses are $299/month. With the Foundayo Savings Card and commercial insurance, copays can be as low as $25/month. | Mostly accurate |
The pricing information is largely correct. The $149 starter price matches published figures exactly. The $349 figure is technically accurate but applies only as a late-refill penalty for the highest doses — the standard maintenance price is $299/month. The segment does not mention the $25/month insurance copay option, which could be significant for viewers evaluating affordability.
For detailed pricing breakdowns, see our Foundayo explainer.
Market Size Projections
| TODAY's Claim | Published Market Data | Verdict |
|---|---|---|
| $73 billion this year, $250 billion by 2034 | Fortune Business Insights (March 2026): GLP-1 RA market valued at $73.39 billion in 2026, projected to reach $254.19 billion by 2034 at 16.8% CAGR. Other analysts (iHealthcare Analyst) project $163.3 billion by 2034 at 11.1% CAGR. | Accurate |
The market projections match Fortune Business Insights data almost exactly. Note that analyst estimates vary widely — some project substantially lower figures — but the numbers cited in the segment are sourced from a reputable market research firm.
Side Effects
| TODAY's Claim | Published Safety Data (ATTAIN-1) | Verdict |
|---|---|---|
| Side effects same as injectables: nausea, GI problems | Foundayo 17.2 mg: nausea (38.8%), diarrhea (22.4%), vomiting (18.5%), constipation (13.4%). These are the same class of side effects as injectable GLP-1 drugs. | Accurate |
| Not more severe, not less severe | GI side effect rates for Foundayo are somewhat higher than some injectables. For comparison, tirzepatide (Zepbound) 15 mg: nausea (26.4%), diarrhea (23.0%), vomiting (13.3%). Orforglipron's nausea rate (38.8%) is notably higher. | Oversimplified |
The types of side effects are identical across the GLP-1 drug class — nausea, diarrhea, vomiting, and constipation are universal. However, the claim that severity is equivalent is an oversimplification. Foundayo's nausea rate (38.8%) is higher than tirzepatide's (26.4%) and semaglutide injection's (~29%). Most side effects are mild to moderate and concentrated during dose titration.
For detailed side effect comparisons, see our GLP-1 side effects guide.
Overall Verdict
The TODAY segment gets the core story right: an oral GLP-1 pill has been FDA-approved, it's less effective than injections but far more convenient, and pricing starts at $149/month. The weight loss data, pricing, and market projections are all accurately reported.
The most significant error is repeatedly calling the drug "Zepbound" when it is actually Foundayo — a completely different medication with a different active ingredient, mechanism, and efficacy profile. For a major national news segment, this is a notable mistake that could confuse patients and healthcare providers.
| Claim | Verdict |
|---|---|
| Drug is called Zepbound | Wrong — it is Foundayo (orforglipron) |
| Can be taken without fasting | Accurate |
| 12% weight loss, 27 pounds | Accurate — ATTAIN-1 shows 12.4%, 27.3 lbs |
| Not as effective as injections | Accurate |
| $149 starter, up to $349/month | Mostly accurate — standard maintenance is $299 |
| Market: $73B to $250B by 2034 | Accurate — matches Fortune BI data |
| Side effects same as injectables | Oversimplified — same types, higher nausea rate |
Frequently Asked Questions
Frequently Asked Questions
What drug did the TODAY show say was approved?
The TODAY segment incorrectly called the new pill "Zepbound." The actual drug is Foundayo (orforglipron), which was FDA-approved on April 1, 2026. Zepbound is the brand name for injectable tirzepatide — a different drug entirely.
Is Foundayo the same as Zepbound?
No. Foundayo (orforglipron) is a daily oral pill that targets only the GLP-1 receptor. Zepbound (tirzepatide) is a weekly injection that targets both GLP-1 and GIP receptors. Both are made by Eli Lilly but they are different drugs with different active ingredients and different levels of weight loss efficacy.
How much weight can you lose on the new GLP-1 pill?
In the ATTAIN-1 clinical trial, patients taking the highest dose of Foundayo lost an average of 12.4% of their body weight (about 27 pounds) over 72 weeks. This is less than injectable options like Zepbound (22.5%) or Wegovy injection (16%), but Foundayo offers the convenience of a daily pill with no fasting requirements.
How much does Foundayo cost per month?
Self-pay pricing starts at $149/month for the 0.8 mg starter dose and goes up to $299/month for maintenance doses (or $349 if refills are delayed beyond 45 days). With commercial insurance and the Foundayo Savings Card, copays can be as low as $25/month.
Sources
- ATTAIN-1 Phase 3 trial results — Orforglipron obesity trial data (Eli Lilly)
- FDA Approves Eli Lilly's Obesity Pill, Foundayo — FDA approval coverage (Time)
- Eli Lilly obesity pill Foundayo gets the FDA green light — FDA approval coverage (NPR)
- How much does Foundayo cost? — Pricing details (Drugs.com)
- GLP-1 Receptor Agonist Market Size — Market projections (Fortune Business Insights)
- SURMOUNT-1 trial — Tirzepatide (Zepbound) Phase 3 data (NEJM)
Medical Disclaimer
The information on this page is for educational purposes only and is not medical advice. Foundayo (orforglipron) is an FDA-approved prescription medication. Always consult a qualified healthcare provider before making decisions about medications or treatments. Do not use this information to self-diagnose, self-treat, or make changes to prescribed therapy.
Sources
Related reading
What Is Foundayo (Orforglipron)? Lilly's FDA-Approved Oral GLP-1 Weight Loss Pill
Eli Lilly's FDA-approved oral GLP-1 pill — 12.4% weight loss, no injections, no fasting. Starting at $149/month.
Orforglipron vs Zepbound (Tirzepatide): Daily Pill vs Weekly Injection
Orforglipron offers 12.4% weight loss as a daily pill starting at $149/month. Zepbound delivers 22.5% as a weekly injection at $299-$449/month. Both from Eli Lilly.
Retatrutide Pill vs Injection: Is There an Oral Formulation?
Retatrutide is injection-only. Here's why there's no pill, how the injection works, and how oral GLP-1 alternatives compare.